Hoffmann-La Roche Opens New R&D Center in Boston
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
What happened
Hoffmann-La Roche and its US subsidiary Genentech opened the Roche Genentech Innovation Centre in Boston. The facility, located at Harvard’s Enterprise Research Campus in Allston, was established to research cardiovascular, renal, and metabolic diseases. The company signed a 10-year lease for the 95,000-square-foot center, which can accommodate up to 500 specialists working in areas like basic research and artificial intelligence.
Why it matters
The new center is part of Hoffmann-La Roche’s broader strategy to invest US$50 billion in US manufacturing and research over the next five years. This expansion reinforces the company's commitment to the US life sciences ecosystem and its role as a major global pharmaceutical player.
Who's involved
- Hoffmann-La RocheSwiss healthcare company establishing a research and development presence in Boston
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AllstonSpeculative
Allston might see increased demand for local services and housing due to the influx of high-skilled jobs.
- MassachusettsSpeculative
Massachusetts could see its economic profile strengthened as a high-tech hub due to the major corporate investment.
How it developed
Newest first. Tap a step to see who reported it.- Nvidia and Hoffmann-La Roche share interest in AI-driven therapeutics following the establishment of a new innovation center in Boston.Sub-event
Hoffmann-La Roche establishes a new R&D center in Boston.1 source
Keep exploring
The entities involved
-
Boston
capital and largest city of Massachusetts, United States
-
Hoffmann-La Roche
Swiss healthcare company
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.
- Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.